Allogene Therapeutics, Inc. (ALLO) — 10-Q Filings
All 10-Q filings from Allogene Therapeutics, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Allogene Narrows Q3 Loss Amid R&D Cuts, Eyes Further Capital
— Nov 6, 2025 Risk: high
Allogene Therapeutics, Inc. reported a net loss of $41.4 million for the three months ended September 30, 2025, a significant improvement from the $66.3 million -
Allogene Narrows Q2 Loss Amid R&D Cuts, Eyes Future Capital Raise
— Aug 13, 2025 Risk: high
Allogene Therapeutics, Inc. reported a net loss of $50.9 million for the three months ended June 30, 2025, an improvement from the $66.4 million net loss in the -
Allogene Therapeutics Files Q1 2025 10-Q
— May 13, 2025 Risk: medium
Allogene Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, based in South San Francisco, CA, operates in the biol -
Allogene Therapeutics Files Q2 2024 10-Q
— Aug 7, 2024 Risk: medium
Allogene Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business oper -
Allogene Therapeutics Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: low
Allogene Therapeutics, Inc. (ALLO) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Allogene Therapeutics, Inc. filed a 10-Q report for the quarter
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX